InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea

Contributed by: PR Newswire

Tags

InDex-Pharmaceuticals

More Like This

InDex Pharmaceuticals is attending the UEGW 2023 congress

InDex Pharmaceuticals discontinues cobitolimod phase III program

InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Induction Study 1 of the phase III program CONCLUDE

InDex Pharmaceuticals announces expected cash balance per March 31, 2024

Calliditas provides patent update

Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO®

Calliditas provides setanaxib patent update

Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment